|Dr. Mark H. N. Corrigan||CEO & Director||N/A||N/A||1958|
|Mr. Justin A. Renz CPA, MST, MBA||CFO & Pres||N/A||N/A||1972|
|Dr. William L. Hunter||Exec. Officer & Director||N/A||N/A||1963|
|Ms. Sheila M. Grant||Chief Operating Officer||N/A||N/A||N/A|
|Mr. David D. McMasters||Gen. Counsel||N/A||N/A||1959|
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Correvio Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.